Clinical Characteristics and Cytogenetics of AML Patients
| Patient . | Sex/Age . | Sample . | Cytogenetics . | % Blast . | FAB . |
|---|---|---|---|---|---|
| 1 | M/72 | PB | 47,xy,+8[25] | 31 | M2 |
| 2 | F/43 | PB | 46,xx,inv(16) (p13;q22) [25] | 39 | M4 |
| 3 | F/44 | PB | pseudodip inv(16),iso22 [1]dip [2] add chgs[22] | 93 | M2 |
| 4 | F/32 | PB | 53,xx,+8,+10,+13,+15,+22, t(16;16)[15] | 99 | M4 |
| 5 | M/22 | BM | 46,xy,iso17(q10)[12]46,xy[8] | 87 | M1 |
| 6 | M/34 | PB | 46,xy[20] | 97 | M1 |
| 7 | M/52 | PB | Hyperdiploid clone 49,xy,+8,+10,+13[21] | 55 | M6 |
| 8 | F/35 | BM | 46,xx,add(14)(p11),del(16)(q21)[5] | 45 | M2 |
| 9 | F/62 | PB | 46xx[20] | 97 | M2 |
| 10 | M/20 | PB | Pseudodiploid clone 46,xy,inv(16)(p13q22)[19] Diploid male[1] | 79 | M2 |
| 11 | F/77 | PB | 46xx,t(1;12;5)(q35;p13;q11), t(3;3)(q23;q29), del(7)(q22) | 82 | M2 |
| 12 | F/46 | PB | 46,xx,t(3;12)[17] 46,xy[3] | 97 | M1 |
| 13 | M/24 | PB | 46,xy,del(7)(q31),inv(16)(p32q22)[11] 46,xy,del(7)(q31)[1]46,xy[10] | 88 | M4 |
| 14 | M/31 | BM | 46xy[4] | 83 | M0 |
| 15 | F/22 | PB | 45,xx,−x,−1,−7,del(11)(q24),+2mar[19] 46,xx[1] | 88 | M1 |
| 16 | F/73 | PB | 46xx | 87 | M1 |
| 17 | M/65 | BM | 46,xy[20] | 85 | M5 |
| 18 | M/72 | PB | 46,xy[19] | 81 | M2 |
| 19 | F/41 | PB | 47,XX,+8[17] | 92 | M7 |
| Patient . | Sex/Age . | Sample . | Cytogenetics . | % Blast . | FAB . |
|---|---|---|---|---|---|
| 1 | M/72 | PB | 47,xy,+8[25] | 31 | M2 |
| 2 | F/43 | PB | 46,xx,inv(16) (p13;q22) [25] | 39 | M4 |
| 3 | F/44 | PB | pseudodip inv(16),iso22 [1]dip [2] add chgs[22] | 93 | M2 |
| 4 | F/32 | PB | 53,xx,+8,+10,+13,+15,+22, t(16;16)[15] | 99 | M4 |
| 5 | M/22 | BM | 46,xy,iso17(q10)[12]46,xy[8] | 87 | M1 |
| 6 | M/34 | PB | 46,xy[20] | 97 | M1 |
| 7 | M/52 | PB | Hyperdiploid clone 49,xy,+8,+10,+13[21] | 55 | M6 |
| 8 | F/35 | BM | 46,xx,add(14)(p11),del(16)(q21)[5] | 45 | M2 |
| 9 | F/62 | PB | 46xx[20] | 97 | M2 |
| 10 | M/20 | PB | Pseudodiploid clone 46,xy,inv(16)(p13q22)[19] Diploid male[1] | 79 | M2 |
| 11 | F/77 | PB | 46xx,t(1;12;5)(q35;p13;q11), t(3;3)(q23;q29), del(7)(q22) | 82 | M2 |
| 12 | F/46 | PB | 46,xx,t(3;12)[17] 46,xy[3] | 97 | M1 |
| 13 | M/24 | PB | 46,xy,del(7)(q31),inv(16)(p32q22)[11] 46,xy,del(7)(q31)[1]46,xy[10] | 88 | M4 |
| 14 | M/31 | BM | 46xy[4] | 83 | M0 |
| 15 | F/22 | PB | 45,xx,−x,−1,−7,del(11)(q24),+2mar[19] 46,xx[1] | 88 | M1 |
| 16 | F/73 | PB | 46xx | 87 | M1 |
| 17 | M/65 | BM | 46,xy[20] | 85 | M5 |
| 18 | M/72 | PB | 46,xy[19] | 81 | M2 |
| 19 | F/41 | PB | 47,XX,+8[17] | 92 | M7 |
Numbers in the square brackets represent the number of metaphases counted, showing a particular chromosomal abnormality. The sum of these numbers represent the total number of metaphases analyzed. Percentage blasts were determined by histological examination of a bone marrow aspirate at the time of sample collection.
Abbreviation: BM, bone marrow.